A study to check reduction in blood glucose level over 24 hours after consuming anti-diabetic medicines- Lobeglitazone or Pioglitazone using Continuous Glucose Monitoring device.
Phase 4
- Conditions
- Health Condition 1: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2023/03/050577
- Lead Sponsor
- Dr Suhas Erande
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
T2DM patient with HbA1c >=7% to <=8.5% and on metformin monotherapy
Exclusion Criteria
Patients taking any other anti-diabetic medication at screening other than metformin
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method